LEADER 05776nam 2202065z- 450 001 9910557432103321 005 20231214133152.0 035 $a(CKB)5400000000043402 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68462 035 $a(EXLCZ)995400000000043402 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aRole of Medical Imaging in Cancers$hVolume 1 210 1$aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (312 pages) 311 $a3-0365-0180-0 311 $a3-0365-0181-9 330 $aundefined 606 $aMedicine 610 $apositron emission tomography 610 $ahead and neck neoplasms 610 $aneovascularization 610 $apathologic 610 $aPET/CT 610 $aurothelial carcinoma 610 $abladder cancer 610 $aupper tract urothelial carcinoma 610 $asurvival 610 $aPET 610 $aPSMA 610 $aprostate 610 $aDCFPyL 610 $aDCFBC 610 $aPSMA-1007 610 $aovarian cancer 610 $arelapse 610 $aSUVmax 610 $atargeted therapy 610 $aprognosis 610 $asoft tissue sarcoma (STS) 610 $apazopanib 610 $adynamic 18F-FDG PET/CT 610 $aSUV 610 $atwo-tissue compartment model 610 $amagnetic resonance imaging 610 $amachine learning 610 $adiffusion 610 $aperfusion 610 $atexture analysis 610 $asquamous cell carcinoma of the head and neck 610 $adiffusion-weighted imaging 610 $amalignant pleural mesothelioma 610 $apleural dissemination 610 $aempyema 610 $apleural effusion 610 $amCRPC 610 $aSPECT/CT 610 $aComputer-assisted diagnosis 610 $aXOFIGO 610 $aTherapy response assessment 610 $acirculating miRNAs 610 $abreast cancer 610 $aimaging parameters 610 $aPET/MRI 610 $abiomarkers 610 $atriple negative breast cancer 610 $aVCAM-1 610 $aSPECT imaging 610 $asdAbs 610 $aHounsfield unit 610 $acomputed tomography 610 $aadipose tissue 610 $aprecision oncology 610 $aFDG-PET/CT 610 $aPERCIST 610 $ametastatic breast cancer 610 $aprostate cancer 610 $a18F-FACBC 610 $arecurrence 610 $ameta-analysis 610 $areview 610 $ameningioma 610 $asomatostatin receptor 610 $aneuroimaging 610 $aradionuclide therapy 610 $abreast 610 $aimaging 610 $amarker 610 $aradiomics 610 $aYin Yang 1 610 $aPDAC 610 $aMesothelin 610 $anoninvasive imaging 610 $areceptor status 610 $amolecular imaging 610 $anuclear medicine 610 $aguidelines 610 $aoverutilization 610 $aepistemology 610 $aconsensus 610 $amantle cell lymphoma 610 $a18F-FDG PET/CT 610 $aDeauville criteria 610 $aRadium-223 610 $aFDG 610 $acastrate resistant prostate cancer 610 $aprogrammed cell death 1 receptor 610 $adiagnostic imaging 610 $aCTLA-4 Antigen 610 $aImmunotherapy 610 $aAdoptive 610 $aradioactive tracers 610 $aradionuclide imaging 610 $aCD8-Positive T-Lymphocytes 610 $aPI-RADS 610 $adiffusion kurtosis imaging 610 $adynamic contrast-enhanced magnetic resonance imaging 610 $a68Gallium-PSMA PET/CT 610 $aprostate-specific-antigen 610 $aPSA kinetics thresholds 610 $abiochemical recurrence 610 $aoptimal cutoff level 610 $anon-small-cell lung cancer 610 $acirculating tumor cells 610 $aimmunotherapy 610 $aresponse to treatment 610 $ahead and neck cancer 610 $aHPV 610 $aEBV 610 $ap16 610 $aMolecular imaging 610 $amiRNA expression 610 $aradiogenomics 610 $aradiomic 610 $adiagnosis 610 $abiomarker 610 $aglioblastoma 610 $aradiation therapy 610 $aMRI 610 $adiffusion tensor imaging 610 $aHodgkin lymphoma 610 $adiffuse large B-cell lymphoma 610 $astaging 610 $aresponse assessment 610 $alocally advanced cervical cancer 610 $aconcurrent chemoradiotherapy 610 $atreatment response 610 $afollow up 610 $acystic tumor 610 $aInternational Consensus Guidelines 610 $aintraductal papillary mucinous neoplasms 610 $apancreatic neoplasms 610 $aPD-1 610 $aPD-L1 610 $aresponse to therapy 610 $aNSCLC 610 $apositron-emission tomography 610 $asingle-photon emission computed tomography 610 $aimmune checkpoint inhibitors 610 $agold nanoparticle 610 $aheat shock protein 70 610 $aspectral-CT 615 0$aMedicine. 700 $aFanti$b Stefano$4edt$0755618 702 $aEvangelista$b Laura$4edt 702 $aFanti$b Stefano$4oth 702 $aEvangelista$b Laura$4oth 906 $aBOOK 912 $a9910557432103321 996 $aRole of Medical Imaging in Cancers$93024548 997 $aUNINA